Table 2.
FLU-IVIG placebo group distribution of the ordinal endpoint at randomization and across the 7 day follow-up period according to the cohort study [17,18].
| Day of Evaluation | Death | ICU | Hospitalized, not in ICU, on oxygen | Hospitalized, not in ICU, not on oxygen | Discharged, not back to normal activities | Discharged, back to normal activities |
|---|---|---|---|---|---|---|
| Day 0 (%)a | 0 | 7.6 | 46.1 | 46.3 | 0 | 0 |
| Day 1 (%) | 0.2 | 6.4 | 40.9 | 43.1 | 8.1 | 1.2 |
| Day 2 (%) | 0.2 | 6.7 | 33.7 | 37.9 | 18.5 | 3.0 |
| Day 3 (%) | 0.2 | 6.7 | 28.8 | 33.0 | 23.2 | 8.1 |
| Day 4 (%) | 0.5 | 6.4 | 21.2 | 26.8 | 31.8 | 13.3 |
| Day 5 (%) | 0.5 | 5.9 | 19.2 | 21.9 | 33.3 | 19.2 |
| Day 6 (%) | 1.0 | 4.9 | 17.7 | 18.5 | 34.7 | 23.2 |
| Day 7 (%) | 1.0 | 4.9 | 16.3 | 14.5 | 36.2 | 27.1 |
a
(%) percentage of patients in the placebo group for the given ordinal endpoint category.